Validation of an Algorithm to Identify Venous Thromboembolism in Health Insurance Claims Data Among Patients with Rheumatoid Arthritis

Purpose Health insurance claims databases provide an opportunity to study uncommon events, such as venous thromboembolism (VTE), in large patient populations. This study evaluated case definitions for identifying VTE among patients treated for rheumatoid arthritis (RA) using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes in claims data. Patients and Methods Study participants were insured adults who received treatment for and had a diagnosis of RA between 2016 and 2020. After a 6-month covariate assessment window, patients were observed for ≥1 month until health plan disenrollment, occurrence of a presumptive VTE, or end of the study (12/31/2020). Presumptive VTEs were identified using predefined algorithms based on ICD-10-CM diagnosis codes, anticoagulant use, and care setting. Medical charts were abstracted to confirm the VTE diagnosis. Performance of primary and secondary (less stringent) algorithms was assessed by calculating the positive predictive value (PPV; primary and secondary objectives). Additionally, a linked electronic health record (EHR) claims database and abstracted provider notes were used as a novel alternative source to validate claims-based outcome definitions (exploratory objective). Results A total of 155 charts identified with the primary VTE algorithm were abstracted. The majority of patients were female (73.5%), with mean (standard deviation) age 66.4 (10.7) years and Medicare insurance (80.6%). Obesity (46.8%), ever smoking (55.8%), and prior evidence of VTE (28.4%) were commonly reported in medical charts. The PPV for the primary VTE algorithm was 75.5% (117/155; 95% confidence interval [CI], 68.7%, 82.3%). A less stringent secondary algorithm had a PPV of 52.6% (40/76; 95% CI, 41.4%, 63.9%). Using an alternative EHR-linked claims database, the primary VTE algorithm PPV was lower, potentially due to the unavailability of relevant records for validation. Conclusion Administrative claims data can be used to identify VTE among patients with RA in observational studies.

[1]  L. Smeeth,et al.  Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  Bernice G Gershenson,et al.  Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases , 2022, Rheumatology and Therapy.

[3]  M. Ritchey,et al.  Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real‐world healthcare databases , 2022, Pharmacoepidemiology and drug safety.

[4]  K. Hornbuckle,et al.  A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. , 2022, Journal of comparative effectiveness research.

[5]  J. Askling,et al.  Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis , 2022, Scandinavian journal of rheumatology.

[6]  Michael Guerzhoy,et al.  Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients. , 2021, Thrombosis research.

[7]  J. Askling,et al.  Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden , 2020, Annals of the Rheumatic Diseases.

[8]  M. Cushman,et al.  Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis , 2020, Research and practice in thrombosis and haemostasis.

[9]  Marc S. Williams,et al.  Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study. , 2020, Thrombosis Research.

[10]  R. Kilpatrick,et al.  Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting , 2019, RMD Open.

[11]  S. Steinhubl,et al.  Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. , 2017, Medical care.

[12]  A. Folsom,et al.  Lifetime Risk of Venous Thromboembolism in Two Cohort Studies. , 2016, The American journal of medicine.

[13]  Michael Friger,et al.  Use of administrative medical databases in population-based research , 2013, Journal of Epidemiology & Community Health.

[14]  S. Schneeweiss,et al.  Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis , 2013, Arthritis care & research.

[15]  F. Sung,et al.  Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study , 2013, Annals of the rheumatic diseases.

[16]  M. Neovius,et al.  Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. , 2012, JAMA.

[17]  L. Tamariz,et al.  A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data , 2012, Pharmacoepidemiology and Drug Safety.

[18]  S. Gabriel,et al.  Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? , 2012, Arthritis and rheumatism.